Abstract B11: Prognostic biomarkers in stage II-III melanoma

Introduction: Biomarkers that predict clinical response in stage II-III melanoma are critical to helping clinicians weigh the potential benefits of immunotherapy against its potential toxicities, as well as allowing for clinical trial population enrichment strategies. We previously defined and validated a 53-immune-gene panel, Melanoma Immune Profile (MIP), predictive of disease-specific survival (DSS). Combination of genomic and tissue-based immune biomarkers may help in the identification of more precise and predictive biomarkers. Methods: We performed quantitative multiplexed immunofluorescence (qmIF) on 64 primary stage II-III melanomas and 14 metastatic melanomas diagnosed at Columbia University Irving Medical Center (CUIMC) between 2000-2014 and 2014-2017, respectively. Formalin-fixed, paraffin-embedded (FFPE) slides were stained and analyzed for DAPI (nuclei), CD3 (T cells), CD8 (cytotoxic T cells, or CTLs), CD68 (macrophages), SOX10 (tumor), HLA-DR (antigen presentation and activation), and Ki67 (proliferation) according to published methods. Spatial relationships were quantified via the inhomogeneous pair correlation function (PCF). NanoString analysis of MIP was performed on extracted RNA from 78 stage II-III melanomas diagnosed between 2000-2014 with known DSS. Results: We find that high CTL and low macrophage density in the stroma correlates with DSS (p 10-micron radius), and these cells are more repulsive of one another in recurrent patients (p=0.008). Further, we validate MIP’s prediction of nonprogression on CUIMC samples (AUC=0.695) and find that MIP correlates with DSS (AUC=0.719, p=0.003). In close evaluation of MIP, we find greater than 1-fold increase in expression of 9 immune genes (p Conclusion: QmIF of stage II-III melanomas shows that the stromal CTL/macrophage ratio is associated with DSS. Further, MIP identifies patients with a low risk of death from melanoma. Combination of the stromal CTL/macrophage ratio with the top genes of MIP also predicts DSS. Combining qmIF and mRNA analyses can therefore stratify stage II-III melanoma patients to receive immunotherapy. Note: This abstract was not presented at the conference. Citation Format: Emanuelle M. Rizk, Robyn D. Gartrell, Andrew Chen, Rui Chang, Douglas K. Marks, Camden L. Esancy, Bret Taback, Basil A. Horst, Charles G. Drake, Raul Rabadan, Yvonne M. Saenger. Prognostic biomarkers in stage II-III melanoma [abstract]. In: Proceedings of the AACR Special Conference on Melanoma: From Biology to Target; 2019 Jan 15-18; Houston, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(19 Suppl):Abstract nr B11.